Abstracts tagged "SLE"

Abstract Number: 1843 • 2016 ACR/ARHP Annual Meeting
Single Cell Expression Quantitative Trait Loci (eQTL) Analysis of Established SLE-Risk Loci in Lupus Patient Monocytes
Yogita Ghodke-Puranik¹, Zhongbo Jin¹, Wei Fan², Mark A. Jensen³, Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin⁴, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁴, Kevin Moder⁴, Vaidehi Chowdhary⁴ and Timothy B. Niewold⁶, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, China, Shanghai, China, ³Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁶Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: While most of the confirmed SLE-risk loci are in or near genes with immune system function, a major unanswered question is how these loci…
Abstract Number: 2840 • 2016 ACR/ARHP Annual Meeting
Are There Genetic Predispositions to Diffuse Large B-Cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?
Sasha Bernatsky¹, Ann E. Clarke², Rosalind Ramsey-Goldman³, Patrick Gaffney⁴, John Spinelli⁵, Sophia Wang⁶ and Timothy J. Vyse⁷, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³FSM, Northwestern University, Chicago, IL, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵School of Population and Public Health, University of British Columbia, Vancouver, QC, Canada, ⁶Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, Duarte, CA, ⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
Are there genetic predispositions to diffuse large B-cell lymphoma (DLBCL) in systemic lupus (SLE)? Sasha Bernatsky1, Ann E. Clarke2, Rosalind Ramsey-Goldman3, Patrick M. Gaffney4,…
Abstract Number: 3105 • 2016 ACR/ARHP Annual Meeting
Relationships Between a Serum Biomarker of B Cell Differentiation and B Cell Activating Factor Suggest Possible Distinct Pathways of Response to Rituximab in Patients with Systemic Lupus Erythematosus
Ricardo Marques¹, Laura Heretiu², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Serviço de Medicina Interna B, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ²Medicine, Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Rituximab (RTX) has been used off-label in refractory SLE with variable clinical outcomes in different cohorts, with no predictive response markers available. However, the…
Abstract Number: 758 • 2016 ACR/ARHP Annual Meeting
Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
Sharzad Emamikia¹, Cidem Gentline², Magnus Backheden³, Katerina Chatzidionysiou², Laurent Arnaud⁴ and Ronald F. van Vollenhoven^2,5, ¹Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Unit for Medical Statistics, Stockholm, Sweden, ⁴Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Dept. of Medicine, Karolinska institutet, Stockholm, Sweden, ⁵Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Corticosteroids (CSs) are widely used in Systemic Lupus Erythematosus (SLE) patients, but have side-effects when used for prolonged periods of time. Our aim was…
Abstract Number: 1000 • 2016 ACR/ARHP Annual Meeting
Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
John McKinnon¹, Junying Zhou², Jenna Hudy¹, Sara Hegab¹ and Kathleen Maksimowicz-McKinnon³, ¹Henry Ford Hospital, Detroit, MI, ²Infectious Diseases, Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Both subclinical cytomegalovirus (CMV) viremia and CMV disease have been associated with adverse outcomes in select immunosuppressed populations, including an increased incidence of other…
Abstract Number: 1754 • 2016 ACR/ARHP Annual Meeting
Double-Negative T (DNT) Cell over-Expressing PD-1 and Helios Is Responsible for Lupus Tissue Injury in Systemic Lupus Erythematosus (SLE): Direct Proof That Increased Interferon Alpha (IFNα) Expression Is Sufficient to Induce SLE in Ifnα-Transgenic Mice
Ken Tsumiyama¹, Chieri Akiyama², Yumi Miyazaki¹, Yasushi Miura², Akira Hashiramoto² and Shunichi Shiozawa¹, ¹Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ²Department of Biophysics, Kobe University Graduate School of Health Science, Kobe, Japan
Background/Purpose: Previous studies strongly suggest that interferon α (IFNα) may be the principal driver of SLE, where increased IFNα and IFNα-regulated gene transcripts explain many of the immune…
Abstract Number: 1910 • 2016 ACR/ARHP Annual Meeting
IL-21 Inhibits Treg Differentiation and Function in SLE By Modulating GATA-3 and CTLA-4
Hiroshi Kato¹ and Andras Perl², ¹Division of Rheumatology/Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, ²Department of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Studies indicate quantitative and qualitative Treg insufficiencies underlying the dysregulated immune response in SLE. However, it is unknown what mechanisms drive the Treg dysfunction…
Abstract Number: 2850 • 2016 ACR/ARHP Annual Meeting
Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
Joan Wither¹, Stephenie Prokopec², Babak Noamani¹, Dennisse Bonilla¹, Zahi Touma³, Carmen Avila-Casado⁴, Heather Reich⁵, James Scholey⁵, Paul R. Fortin⁶, Paul Boutros² and Carolina Landolt-Marticorena¹, ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Pathology, University Health Network, Toronto, ON, Canada, ⁵Nephrology, University Health Network, Toronto, ON, Canada, ⁶Université Laval, CHU de Québec, Québec, QC, Canada
Background/Purpose: The relapsing and remitting nature of lupus nephritis (LN) poses a challenge to clinicians who must balance the risk of long term kidney damage…
Abstract Number: 3110 • 2016 ACR/ARHP Annual Meeting
Rab4A Is Required for Development of Tregs, Restricts Antiphospholipid Antibody Production and Pro-Inflammatory Expansion of Macrophages and Neutrophils, and Blocks Pristane-Induced Intra-Alveolar Hemorrhage in a Mouse Model of SLE
Zachary Oaks¹, Thomas Winans¹, Nick Huang¹, Sarah Blair¹, Miguel Beckford¹, Katalin Banki² and Andras Perl³, ¹SUNY, Syracuse, NY, ²Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ³Department of Medicine, Upstate Medical University, Syracuse, NY
Background/Purpose: Polymorphic haplotypes of the HRES-1 endogenous retrovirus at the 1q42 chromosomal locus have been associated with lupus susceptibility, in particular, with predisposition to antiphospholipid…
Abstract Number: 759 • 2016 ACR/ARHP Annual Meeting
Gene Signature for Glucocorticoid, from in Vitro to In Vivo
Yanhua Sarah Hu¹, Somnath Bandyopadhyay¹, Deborah Furst¹, A Johnsen¹, Robert Latek¹, Steven G. Nadler² and Julie Carman³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ, ³Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Steroids are widely used in clinical practice for treating systemic lupus erythematosus (SLE), and can have a strong effect on immune cells in Whole…
Abstract Number: 1048 • 2016 ACR/ARHP Annual Meeting
Differences in Clinical Manifestations of SLE Across Four Racial/Ethnic Groups: The California Lupus Surveillance Project (CLSP)
Ernest Maningding¹, Jinoos Yazdany², Laura Trupin², Chris Tonner³, Charles G. Helmick⁴ and Maria Dall'Era⁵, ¹Internal Medicine, Santa Clara Valley Medical Center, San Jose, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴CDC, Atlanta, GA, ⁵Division of Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The CLSP is a population-based registry of individuals with SLE residing in San Francisco County, California from 2007 – 2009. The registry has a…
Abstract Number: 1755 • 2016 ACR/ARHP Annual Meeting
Dendritic Cell-Specific Loss of Caspase 8 Incites Symptoms of Neuropsychiatric Systemic Lupus Erythematosus
Hadijat Makinde¹, Harris R. Perlman² and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE), and although DCs from SLE patients exhibit elevated…
Abstract Number: 1969 • 2016 ACR/ARHP Annual Meeting
Peer Approaches to Lupus Self-Management (PALS): A Novel Lupus Peer Mentorship Intervention
Edith M. Williams¹, Leonard Egede², Jim Oates³, Delia Voronca² and Mulugeta Gebregziabher², ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that is associated with increased morbidity, mortality, health care costs and decreased quality of life.…
Abstract Number: 2851 • 2016 ACR/ARHP Annual Meeting
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Donald Massenburg, Justine Oldenberg, Amanda Sell, Tristan Krause and Alvin F. Wells, Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: The SLE-key® test to Rule Out lupus was developed by ImmunArray Ltd using serum samples of 246 SLE patients and 252 self-declared healthy controls.…
Abstract Number: 3172 • 2016 ACR/ARHP Annual Meeting
Temporal Trends in SLE Mortality According to Sex, Race, Ethnicity, and Geographic Region in the United States over the Past Five Decades
Eric Yen¹, Magda Shaheen², Jennifer MP Woo¹, Neil Mercer¹, Lewei Duan¹, Ning Li¹, Arun Karlamangla¹, Deborah K. McCurdy¹ and Ram R. Singh¹, ¹UCLA, Los Angeles, CA, ²Charles R. Drew University of Medicine and Science, Los Angeles, CO
Background/Purpose: Over the past half-century, diagnostic and therapeutic developments for SLE have led to dramatic improvements in the 5- and 10-year survival. Whether these achievements…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].